Skip to content

A Cross-specialty Collaboration Platform for Mucopolysaccharidosis Confirmative Diagnosis

The Establishment of a Cross-specialty Collaboration Platform Among Different Medical Specialties Based on High-risk Criteria for Mucopolysaccharidosis Confirmative Diagnosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03017677
Enrollment
100
Registered
2017-01-11
Start date
2018-01-01
Completion date
2020-12-31
Last updated
2018-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mucopolysaccharidoses

Brief summary

In this study the investigators is aimed to establish the MPS screening algorithm for high risk patients who had medical history of previous surgical repair or presence of inguinal and/or umbilical hernia with combination of any ENT related surgery or examination in Taiwan.

Detailed description

Mucopolysaccharidoses (MPS) are a group of inherited lysosomal storage disorders. In individuals with MPS disorders, have deficiency or malfunction of specific lysosomal enzymes leads to an abnormal accumulation of certain complex carbohydrates (mucopolysaccharides or glycosaminoglycans) in the arteries, skeleton, eyes, joints, ears, skin, and/or teeth. These accumulations may also be found in the respiratory system, liver, spleen, central nervous system, blood, and bone marrow. This accumulation eventually causes progressive damage to cells, tissues, and various organ systems of the body. Due to such an extreme variability in clinical presentation as well as wide range of disease spectrum, but insufficient MPS disease awareness in Taiwan, these resulted in a delay diagnosis or even miss diagnosis with other clinical symptom thus patient often received inappropriate treatment. In order to address the current issue of delay diagnosis among MPS patient, it is critical to develop a MPS screening algorithm for high risk patients in Taiwan.

Interventions

None listed

Sponsors

BioMarin Pharmaceutical
CollaboratorINDUSTRY
Mackay Memorial Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 20 Years
Healthy volunteers
No

Inclusion criteria

* The subject is 0-20 years of age. * The subject had medical history of previous surgical hernia repair or presence of inguinal and/or umbilical hernia. * The subject had or is scheduled for ENT surgery for any of the following, alone or in combination with adenoidectomy, tonsillectomy, ear tube insertion/tympanostomy, tracheotomy and bronchoscopy * The subject who is willing and able to provide written, signed informed consent, or by a legally authorized representative after the nature of the study has been explained and prior to any research-related procedures.

Exclusion criteria

-The subject has a current confirmed diagnosis of any MPS disorder.

Design outcomes

Primary

MeasureTime frame
To evaluate the positive screening rate of MPS subject (I, II VI and IV) under ENT screening algorithm in Taiwan3 Years

Secondary

MeasureTime frame
To evaluate the data collection of patient profile which include urine GAG data, disaccharides patterns, enzyme activity, genetic pattern and medical history of MPS (I, II VI and IV) patients.3 Years

Contacts

Primary ContactHsiang-Yu Lin, MD
lxc46199@ms37.hinet.net+886-2-2543-3535

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026